These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 16315942

  • 1. [Combination immunotherapy using autologous tumor-stimulated lymphocytes and trastuzumab (Herceptin) for the patients with recurrent breast cancer].
    Toh U, Fujii T, Miwa K, Yokoyama G, Yamaguchi M, Kawamura D, Machida E, Shirouzu K, Yamana H.
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1789-91. PubMed ID: 16315942
    [Abstract] [Full Text] [Related]

  • 2. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M, Morisaki T, Kuroki H, Tasaki A, Yamanaka N, Matsumoto K, Nakamura K, Onishi H, Baba E, Katano M.
    Anticancer Res; 2003 Oct; 23(6a):4443-9. PubMed ID: 14666732
    [Abstract] [Full Text] [Related]

  • 3. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
    Breast Cancer Res; 2005 Oct; 7(4):R436-43. PubMed ID: 15987448
    [Abstract] [Full Text] [Related]

  • 4. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R, Okumura Y, Arima N.
    Breast Cancer; 2008 Oct; 15(1):57-64. PubMed ID: 18224396
    [Abstract] [Full Text] [Related]

  • 5. Perspectives of immunotherapy in metastatic breast cancer.
    Lüftner D, Pollmann D, Schildhauer S, Sehouli J, Possinger K.
    Anticancer Res; 2005 Oct; 25(6C):4599-604. PubMed ID: 16334149
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM.
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M.
    Orv Hetil; 2001 Nov 18; 142(46):2563-8. PubMed ID: 11770175
    [Abstract] [Full Text] [Related]

  • 11. Potential use of humanized antibodies in the treatment of breast cancer.
    Schaefer NG, Pestalozzi BC, Knuth A, Renner C.
    Expert Rev Anticancer Ther; 2006 Jul 18; 6(7):1065-74. PubMed ID: 16831078
    [Abstract] [Full Text] [Related]

  • 12. Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial.
    Horton JK, Halle J, Ferraro M, Carey L, Moore DT, Ollila D, Sartor CI.
    Int J Radiat Oncol Biol Phys; 2010 Mar 15; 76(4):998-1004. PubMed ID: 19560883
    [Abstract] [Full Text] [Related]

  • 13. Study of the measurement of serum extracellular domain of HER-2/neu protein with CLIA method.
    Kuroda N, Kontani K, Kajikawa T, Taminato T.
    Rinsho Byori; 2010 Jun 15; 58(6):541-52. PubMed ID: 20662264
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
    Palmieri C, Shah D, Krell J, Gojis O, Hogben K, Riddle P, Ahmad R, Tat T, Fox K, Porter A, Mahmoud S, Kirschke S, Shousha S, Gudi M, Coombes RC, Leonard R, Cleator S.
    Clin Breast Cancer; 2011 Apr 15; 11(2):93-102. PubMed ID: 21569995
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
    Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L.
    Eur J Surg Oncol; 2011 Oct 15; 37(10):856-63. PubMed ID: 21843921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.